Bharat Biotech begins phase III trials of clot-busting drugFebruary 4th, 2011 - 9:15 pm ICT by IANS
Hyderabad, Feb 4 (IANS) Bharat Biotech (www.bharatbiotech.com) Friday announced that it has initiated Phase III clinical trials in India of THR-100 (Staphylokinase), a clot-busting drug for patients suffering an acute myocardial infarction (AMI).The trial is expected to recruit approximately 120 patients, said a statement by Hyderabad-based Bharat Biotech, a leading vaccine manufacturer.
Bharat Biotech entered into a license agreement in 2006 with ThromboGenics for the manufacture, clinical development and commercialization of THR-100 as a replacement for established thrombolytics, such as streptokinase and urokinase.
THR-100, a novel variant of Recombinant Staphylokinase, is a thrombolytic agent developed by ThromboGenics for the treatment of AMI and other vascular diseases, based on its ability to dissolve blood clots.
Bharat Biotech anticipates that the Phase III trial with THR-100 will be completed in the second half of 2011. The results of this Phase III trial will pave the way for thrombolytic to be filed for marketing approval by Bharat Biotech with Indian regulatory authorities.
- Controller clears clot-buster drug for human trial - Aug 17, 2012
- India's Bharat Biotech to sell $1 diarrhoea vaccine - Jun 06, 2011
- Chandigarh Research Institute develops medicine for clots busting linked to heart attacks - Aug 08, 2009
- Bharat Biotech receives $4 million award for new vaccine - Jun 18, 2012
- Biocon net profit up 20 percent in second quarter - Oct 22, 2010
- New device removes clots from brain - Aug 27, 2012
- Cuba to test new AIDS vaccine - Mar 07, 2012
- Clot-busting drug 'works best for strokes caused by blood clots' - Nov 10, 2010
- Clot busting drug could improve stroke treatment - May 29, 2011
- Over 250 companies to participate in BioAsia 2012 - Feb 07, 2012
- Bharat Biotech vaccine doses touch one-billion mark - Feb 03, 2010
- Drug from Indian spice builds brain cells after stroke - Feb 10, 2011
- Ranbaxy boosts presence in Africa with malaria drug - May 11, 2012
- Cuba to start clinical trials of pneumonia vaccine - May 04, 2012
- Intense light reduces heart attack risks - Apr 26, 2012
Tags: acute myocardial infarction, ami, blood clots, clinical trials, commercialization, India, license agreement, myocardial infarction, novel variant, phase iii, regulatory authorities, second half, streptokinase, thr, thrombogenics, thrombolytic agent, thrombolytics, urokinase, vaccine manufacturer, vascular diseases